Boston Scientific (BSX) Faces WATCHMAN Slowdown But Analysts Still See Upside
Boston Scientific (BSX) Faces WATCHMAN Slowdown But Analysts Still See Upside.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
With an upside potential of 62.55%, Boston Scientific Corporation (NYSE: BSX ) is among the 12 Strong Buy Stocks with High Upside According to Analysts .
On July 8, Needham analyst Mike Matson lowered the firm's price target on Boston Scientific Corporation (NYSE:BSX) to $57 from $77 while maintaining a Buy rating on the shares. The adjustment followed management commentary indicating that sales of the company's WATCHMAN device have slowed, with expectations for sequentially flat sales during the second and third quarters. According to Needham, management attributed part of the slowdown to workflow-related challenges, while the firm believes recent clinical trial developments and reimbursement dynamics may also be affecting growth. Despite these near-term pressures, Needham continues to view Boston Scientific favorably, given its broader portfolio strength and long-term growth opportunities.
Earlier, on July 6, Evercore ISI lowered its price target on Boston Scientific Corporation (NYSE:BSX) to $65 from $78 while reiterating an Outperform rating. In its second-quarter preview of the medical technology sector, the firm highlighted generally healthy procedure volumes and capital spending trends across healthcare markets. While acknowledging some product-specific challenges, Evercore continues to view Boston Scientific as a well-positioned industry leader capable of benefiting from favorable long-term healthcare and medical device demand trends.
Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific Corporation (NYSE:BSX) is a global medical technology company that develops, manufactures, and markets minimally invasive medical devices. Although analysts have reduced their price targets, Boston Scientific's diversified product portfolio, strong position in multiple high-growth medical markets, and continued Buy and Outperform ratings support a constructive long-term investment outlook, making it one of the strong buy stocks with high upside according to analysts.
While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
READ NEXT: 12 Best Quality Stocks to Buy and Hold for the Next Decade and 7 Best Fusion Energy Development Stocks to Buy .
Sinergia Empresarial continuará el seguimiento de esta información sobre boston Scientific (BSX) Faces WATCHMAN Slowdown But Analysts Still See Upside y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.
